HomeDiscoveryPublicationsPublications 2012

Publications 2012



Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies
Weiss GJ, Hidalgo M, Borad MJ, Laheru D, Tibes R, Ramanathan RK, Blaydorn L, Jameson G, Jimeno A, Isaacs JD, Scaburri A, Pacciarini MA, Fiorentini F, Ciomei M, Von Hoff DD
Invest New Drugs (2012) 30(6), 2334-2343

The interaction of nemorubicin metabolite PNU-159682 with DNA fragments d(CGTACG)(2), d(CGATCG)(2) and d(CGCGCG)(2) shows a strong but reversible binding to G:C base pairs
Mazzini S, Scaglioni L, Mondelli R, Caruso M, Sirtori FR
Bioorg Med Chem (2012), 20(24),6979-6988

Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model
Fraedrich K, Schrader J, Ittrich H, Keller G, Gontarewicz A, Matzat V, Kromminga A, Pace A, Moll J, Bläker M, Lohse AW, Hörsch D, Brümmendorf TH, Benten D
Clin Cancer Res (2012), 18(17), 4621-4632

Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125
Caporali S, Alvino E, Levati L, Esposito AI, Ciomei M, Brasca MG, Del Bufalo D, Desideri M, Bonmassar E, Pfeffer U, D’Atri S
Biochem Pharmacol (2012) Jun 13. [Epub ahead of print]

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
Oliva P, Decio A, Castiglioni V, Bassi A, Pesenti E, Cesca M, Scanziani E, Belotti D, Giavazzi R
Br J Cancer
(2012), 107(2), 360-369

Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists
Perez HL, Banfi P, Bertrand J, Cai ZW, Grebinski JW, Kim K, Lippy J, Modugno M, Naglich J, Schmidt RJ, Tebben A, Vianello P, Wei DD, Zhang L, Galvani A, Lombardo LJ, Borzilleri RM
Bioorg Med Chem Lett
(2012), 22(12), 3946-3950

Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists
Schroeder GM, Wei D, Banfi P, Cai ZW, Lippy J, Menichincheri M, Modugno M, Naglich J, Penhallow B, Perez HL, Sack J, Schmidt RJ, Tebben A, Yan C, Zhang L, Galvani A, Lombardo LJ, Borzilleri RM
Bioorg Med Chem Lett
(2012), 22(12), 3951-3956

Alk inhibitors, a Pharmaceutical Perspective
Ardini E, Galvani A
Front Oncol
(2012), 2(17), 1-8

Development of Biochemical Assays for the Identification of eIF4E-Specific Inhibitors
Visco C, Perrera C, Thieffine S, Sirtori FR, D’Alessio R, Magnaghi P
J Biomol Screen
(2012), 17(5), 581-92

Molecular Recognition of T:G Mismatched Base Pairs in DNA as Studied by Electrospray Ionization Mass Spectrometry.
Riccardi Sirtori F, Aldini G, Colombo M, Colombo N, Malyszko J, Vistoli G, D’Alessio R
(2012), 7(6), 1112-22

Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells
Bosotti R, Carpinelli P, Healy S, Locatelli G, Cappella P, Lanfrancone L, Calogero R, Moll J, Isacchi A.
(2012), 494(2), 202-8

In Vivo Imaging of Lymph Node Migration of MNP- and (111)In-Labeled Dendritic Cells in a Transgenic Mouse Model of Breast Cancer (MMTV-Ras)
Martelli C, Borelli M, Ottobrini L, Rainone V, Degrassi A, Russo M, Gianelli U, Bosari S, Fiorini C, Trabattoni D, Clerici M, Lucignani G
Mol Imaging Biol
(2012), 14(29), 183-96

NMS-P937, an orally available, specific, small molecule Polo-Like Kinase 1 inhibitor with antitumor activity in solid and haematological malignancies
Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, Cappella P, Caruso M, Casolaro A, Ciavolella A, Cucchi U, De Ponti A, Felder E, Fiorentini F, Galvani A, Gianellini LM, Giorgini ML, Isacchi A, Lansen J, Pesenti E, Rizzi S, Rocchetti M, Sola F, Moll J
Mol Cancer Ther.
(2012), 11(4), 1006-1016

The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding
Felder ER, Badari A, Disingrini T, Mantegani S, Orrenius C, Avanzi N, Isacchi A, Salom B
Mol Divers.
(2012), 16(1), 21-51

5-(2-Amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro–pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors
Beria I, Caruso M, Valsasina B, Ballinari D, Bertrand J, Brasca MB, Caldarelli M, Cappella P, Fiorentini F, Gianellini L, Scolaro A
Bioorganic & Medicinal Chemistry Letters
(2012), 22(1), 96-101

Labeling Protocols for In Vivo Tracking of Human Skeletal Muscle Cells (HSkMCs) by Magnetic Resonance and Bioluminescence Imaging
Libani IV, Lucignani G, Gianelli U, Degrassi A, Russo M, Bosari S, Clerici M, Ottobrini L.
Mol Imaging Biol.
(2012), 14(1), 47-59